NFE2L3
| Nuclear factor (erythroid-derived 2)-like 3 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||
| Symbols | NFE2L3 ; NRF3 | ||||||||||||
| External IDs | OMIM: 604135 MGI: 1339958 HomoloGene: 3168 GeneCards: NFE2L3 Gene | ||||||||||||
| |||||||||||||
| Orthologs | |||||||||||||
| Species | Human | Mouse | |||||||||||
| Entrez | 9603 | 18025 | |||||||||||
| Ensembl | ENSG00000050344 | ENSMUSG00000029832 | |||||||||||
| UniProt | Q9Y4A8 | Q9WTM4 | |||||||||||
| RefSeq (mRNA) | NM_004289 | NM_010903 | |||||||||||
| RefSeq (protein) | NP_004280 | NP_035033 | |||||||||||
| Location (UCSC) | Chr 7: 26.19 – 26.23 Mb | Chr 6: 51.43 – 51.46 Mb | |||||||||||
| PubMed search | |||||||||||||
Nuclear factor erythroid 2-related factor 3, also known as NF-E2-related factor 3 or Nrf3, is a transcription factor that in humans is encoded by the NFE2L3 gene.[1][2]
Function
This gene encodes a member of the cap 'n' collar basic-region leucine zipper (bZIP) family of transcription factors. The encoded protein heterodimerizes with small musculoaponeurotic fibrosarcoma factors (MAF) to bind antioxidant response elements in target genes. This protein is a membrane bound glycoprotein that is targeted to the endoplasmic reticulum and the nuclear envelope.[1]
References
- ↑ 1.0 1.1 "Entrez Gene: nuclear factor (erythroid-derived 2)-like 3".
- ↑ Kobayashi A, Ito E, Toki T, Kogame K, Takahashi S, Igarashi K, Hayashi N, Yamamoto M (March 1999). "Molecular cloning and functional characterization of a new Cap'n' collar family transcription factor Nrf3". J. Biol. Chem. 274 (10): 6443–52. doi:10.1074/jbc.274.10.6443. PMID 10037736.
Further reading
- Davila S, Froeling FE, Tan A et al. (2010). "New genetic associations detected in a host response study to hepatitis B vaccine.". Genes Immun. 11 (3): 232–8. doi:10.1038/gene.2010.1. PMID 20237496.
- Sankaranarayanan K, Jaiswal AK (2004). "Nrf3 negatively regulates antioxidant-response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene.". J. Biol. Chem. 279 (49): 50810–7. doi:10.1074/jbc.M404984200. PMID 15385560.
- Chénais B, Derjuga A, Massrieh W et al. (2005). "Functional and placental expression analysis of the human NRF3 transcription factor.". Mol. Endocrinol. 19 (1): 125–37. doi:10.1210/me.2003-0379. PMID 15388789.
- Nouhi Z, Chevillard G, Derjuga A, Blank V (2007). "Endoplasmic reticulum association and N-linked glycosylation of the human Nrf3 transcription factor.". FEBS Lett. 581 (28): 5401–6. doi:10.1016/j.febslet.2007.10.041. PMID 17976382.
- Hillier LW, Fulton RS, Fulton LA et al. (2003). "The DNA sequence of human chromosome 7.". Nature 424 (6945): 157–64. doi:10.1038/nature01782. PMID 12853948.
- Terui K, Takahashi Y, Kitazawa J et al. (2000). "Expression of transcription factors during megakaryocytic differentiation of CD34+ cells from human cord blood induced by thrombopoietin.". Tohoku J. Exp. Med. 192 (4): 259–73. doi:10.1620/tjem.192.259. PMID 11286316.
- Gerhard DS, Wagner L, Feingold EA et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- "Toward a complete human genome sequence". Genome Res. 8 (11): 1097–108. 1998. doi:10.1101/gr.8.11.1097. PMID 9847074.
- Zhang Y, Kobayashi A, Yamamoto M, Hayes JD (2009). "The Nrf3 transcription factor is a membrane-bound glycoprotein targeted to the endoplasmic reticulum through its N-terminal homology box 1 sequence". J. Biol. Chem. 284 (5): 3195–210. doi:10.1074/jbc.M805337200. PMID 19047052.
- Strausberg RL, Feingold EA, Grouse LH et al. (2002). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
This article incorporates text from the United States National Library of Medicine, which is in the public domain.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||